Skip to main content
SpringerLink
Log in

Switching to biosimilar trastuzumab saves budget costs

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2018 euros

Reference

  • Lee SM, et al. Budget Impact of Switching to Biosimilar Trastuzumab (CT-P6) for the Treatment of Breast Cancer and Gastric Cancer in 28 European Countries. BioDrugs : 14 Jun 2019. Available from: URL: http://doi.org/10.1007/s40259-019-00359-0

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Switching to biosimilar trastuzumab saves budget costs. PharmacoEcon Outcomes News 831, 31 (2019). https://doi.org/10.1007/s40274-019-6019-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-019-6019-y

Search

Navigation